임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 21-06-06 19:46
논문번호 225
논문제목(영문) Comparison of Resolute zotarolimus-eluting and Xience everolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES VI trial
국내외구분 국외 SCI여부 SCI
연구책임자역할 공저자
주저자명 Do-Yoon Kang
교신저자명 Seung-Jung Park
공동저자명 Cheol Hyun Lee, Pil Hyung Lee, Jung-Min Ahn , Seung-Whan Lee, Young-Hak Kim , Seong-Wook Parka , Chang Wook Name , Yun Seok Choi , Seung-Woon Rh , Jang Hyun Cho , Weon Kim, Sung-Ho Herh , Myung Ho Jeong, et at.
게제년월일 2018-10-21
ISSN 1473-5830
Impact Factor 1.080
학술지명 coronary artery disease
서지사항 0집 / 30권 / 1호,   페이지(59 - 66)
요약초록문
(Abstract) 입력		 Background: Outcomes for stent-based coronary intervention of lesions with long diseased segments remain relatively unfavorable. This study sought to compare the efficacy of Resolute zotarolimus-eluting stents (R-ZES) and Xience everolimus-eluting stents (EES) for very long coronary lesions.

Methods and results: This randomized, multicenter, prospective trial compared the use of R-ZES with EES for very long (≥50 mm) native coronary lesions. The primary end point was in-segment late luminal loss at 12-month angiographic follow-up. A total of 400 patients were needed to assess the primary end point. However, owing to very slow enrollment of patients, this trial was early terminated (302 patients were enrolled), and thus, this report provides descriptive information on primary and secondary end points. The R-ZES and EES groups had similar baseline characteristics. Lesion length was 49.6±10.2 and 50.6±13.3 mm in the R-ZES and EES groups, respectively (P=0.47). The number of stents used at the target lesion was 2.1±0.3 and 2.2±0.5, respectively. Twelve-month angiographic follow-up was performed in 50% of eligible patients. In-segment late luminal loss did not significantly differ between the R-ZES and EES groups (0.17±0.57 vs. 0.09±0.43 mm, P=0.32). In-segment binary restenosis rates were 8.1 and 5.3% in the R-ZES and EES groups, respectively (P=0.49). There were no significant between-group differences in the rate of adverse events (death, myocardial infarction, stent thrombosis, target lesion revascularization, and composite outcomes).

Conclusion: For patients with very long native coronary artery disease, R-ZES and EES implantation showed comparable angiographic and clinical outcomes through 1 year of follow-up.
파일  C225. Comparison of Resolute zotarolimus-eluting and Xience everolimus-elut~.pdf (206.7K) DATE : 2021-06-06 19:47:09